Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals, a leader in mitochondrial biology, is advancing a new class of medicines designed to address a primary driver of cardio-metabolic diseases: obesity. Harnessing the natural process of mitochondrial uncoupling, Rivus’ Controlled Metabolic Accelerators (CMAs) provide a new, measured approach to reducing fat throughout the body. By doing so, CMAs can reduce the risk of cardio-metabolic disease with the aim of enabling healthier lives for millions.